Internship

Immunology Co-op Spring 2025

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

Winter/Spring internship opportunity from 1/21/25 to 6/20/25; must be available for the entire duration.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • Currently enrolled in a Master’s or PhD program in Immunology, Cell Biology, Molecular Biology, or a related field.
  • Hands-on experience with Flow Cytometry, ELISA, Luminex, and cell-based assays is required.
  • Strong analytical and problem-solving skills with the ability to interpret complex data.
  • Excellent organizational skills and attention to detail.
  • Ability to work independently and collaboratively within a team.
  • Proficient in data analysis software (e.g., FlowJo, GraphPad Prism) and Microsoft Office Suite.
  • Strong verbal and written communication skills.
Responsibilities
  • Design, execute, and analyze Flow Cytometry experiments to characterize immune cell populations and assess functional markers.
  • Perform ELISA and Luminex assays to quantify cytokines, chemokines, and other soluble factors in biological samples.
  • Conduct cell-based assays to evaluate immune cell function, including proliferation, cytotoxicity, and cytokine production.
  • Maintain accurate and detailed records of experiments, including data analysis and interpretation.
  • Assist in the development and optimization of new protocols for immunological assays.
  • Collaborate with cross-functional teams to support ongoing research projects.
  • Present experimental findings in lab meetings and contribute to the preparation of scientific manuscripts.
  • Ensure compliance with all safety and regulatory requirements within the laboratory.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?